Literature DB >> 10389852

The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

A B Walker1, P D Chattington, R E Buckingham, G Williams.   

Abstract

Human obesity is associated with insulin resistance, hyperinsulinemia, and a predisposition to hypertension and vascular disease, the origin of which may lie in impairment of endothelial function. We tested the effects of the thiazolidinedione rosiglitazone on blood pressure and endothelial function in insulin-resistant fatty Zucker rats, which display hypertension and abnormal endothelial cell function. We studied fatty Zucker rats given rosiglitazone maleate (50 micromol/kg diet; n = 8) for 9-12 weeks (treated fatty), untreated fatty rats (n = 8), and lean rats (n = 8) given diet alone. At the end of the study, systolic blood pressure was significantly higher in untreated fatty (147 +/- 5 mmHg) than in lean rats (125 +/- 2 mmHg; P < 0.05), but rosiglitazone treatment prevented the development of hypertension in fatty rats (123 +/- 1 mmHg). Fasting hyperinsulinemia in untreated fatty rats (28.7 +/- 6.0 ng/ml) was significantly lowered by rosiglitazone (7.0 +/- 1.4 ng/ml; P < 0.05 vs. untreated fatty), but remained significantly higher than the levels seen in lean rats (1.5 +/- 0.4 ng/ml; P < 0.01). Mesenteric arteries were studied in a myograph. Maximal acetylcholine chloride (1.1 micromol/l)-induced relaxation of norepinephrine hydrochloride (NE)-induced constriction was impaired in untreated fatty (62.4 +/- 3.4%) vs. lean (74.3 +/- 3.5%; P = 0.01) rats; this defect was partially prevented by rosiglitazone (66.5 +/- 3.0%; P = 0.01 vs. untreated fatty). Insulin (50 mU/l) significantly attenuated the contractile response to NE in lean rats (14.7 +/- 3.3%; P = 0.02); this vasodilator effect of insulin was absent in untreated fatty rats at concentrations of 50-5,000 mU/l, but was partially restored by rosiglitazone (9.7 +/- 2.5% attenuation; P = 0.02 vs. no insulin). Thus, rosiglitazone prevents the development of hypertension and partially protects against impaired endothelial function associated with insulin resistance. These latter effects may contribute to the drug's antihypertensive properties.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389852     DOI: 10.2337/diabetes.48.7.1448

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  37 in total

Review 1.  Modern pharmacotherapies for type 2 diabetes mellitus.

Authors:  S H Hsia
Journal:  J Natl Med Assoc       Date:  2001-09       Impact factor: 1.798

Review 2.  Enhancing insulin action: from chemical elements to thiazolidinediones.

Authors:  R Perfetti; K Chamie
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

3.  Peroxisome proliferator-activated receptor gamma ligands and atherosclerosis: ending the heartache.

Authors:  E D Rosen; B M Spiegelman
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 4.  Hypertension and insulin disorders.

Authors:  Michinori Imazu
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

5.  Possible involvement of IGF-1 receptor and IGF-binding protein in insulin-induced enhancement of noradrenaline response in diabetic rat aorta.

Authors:  Tsuneo Kobayashi; Akihito Kaneda; Katsuo Kamata
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

6.  Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats.

Authors:  A A Bosco; A C Lerario; R F Santos; B L Wajchenberg
Journal:  Diabetologia       Date:  2003-11-04       Impact factor: 10.122

7.  Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.

Authors:  Adam G Goodwill; Stephanie J Frisbee; Phoebe A Stapleton; Milinda E James; Jefferson C Frisbee
Journal:  Microcirculation       Date:  2009-11       Impact factor: 2.628

8.  Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma.

Authors:  Yau-Sheng Tsai; Hyo-Jeong Kim; Nobuyuki Takahashi; Hyung-Suk Kim; John R Hagaman; Jason K Kim; Nobuyo Maeda
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

Review 9.  Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Antona J Wagstaff; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Peroxisome proliferator-activated receptors in diabetic nephropathy.

Authors:  Shinji Kume; Takashi Uzu; Keiji Isshiki; Daisuke Koya
Journal:  PPAR Res       Date:  2009-03-04       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.